| Market Cap | 698.15M | P/E | - | EPS this Y | 108.00% | Ern Qtrly Grth | - |
| Income | -8.32M | Forward P/E | - | EPS next Y | 216.70% | 50D Avg Chg | 7.00% |
| Sales | 376.97M | PEG | 223.75 | EPS past 5Y | -5.25% | 200D Avg Chg | 26.00% |
| Dividend | N/A | Price/Book | 2.49 | EPS next 5Y | 2.00% | 52W High Chg | -27.00% |
| Recommedations | 1.40 | Quick Ratio | 2.65 | Shares Outstanding | 41.89M | 52W Low Chg | 77.00% |
| Insider Own | 5.52% | ROA | 2.07% | Shares Float | 34.51M | Beta | 1.74 |
| Inst Own | 85.91% | ROE | -2.90% | Shares Shorted/Prior | 3.06M/3.17M | Price | 17.08 |
| Gross Margin | 64.63% | Profit Margin | -2.22% | Avg. Volume | 168,491 | Target Price | 30.32 |
| Oper. Margin | 8.48% | Earnings Date | Oct 31 | Volume | 88,784 | Change | -0.99% |
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
| Needham | Buy | Sep 27, 24 |
| Stifel | Buy | Sep 13, 24 |
| Needham | Buy | Aug 9, 24 |
| Oppenheimer | Outperform | Aug 9, 24 |
| Stifel | Buy | Aug 9, 24 |
| Lake Street | Buy | Jul 2, 24 |
| Stifel | Buy | May 7, 24 |
| Needham | Buy | May 7, 24 |
| Needham | Buy | Apr 8, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Horton Amy | VP, Chief Accounting.. VP, Chief Accounting Officer | Dec 15 | Sell | 19 | 14,397 | 273,543 | 124,040 | 12/19/23 |
| Horton Amy | VP, Chief Accounting.. VP, Chief Accounting Officer | Dec 15 | Option | 16.3 | 14,397 | 234,671 | 138,437 | 12/19/23 |
| Horton Amy | VP, Chief Accounting.. VP, Chief Accounting Officer | Nov 27 | Sell | 17.34 | 2,101 | 36,431 | 105,599 | 11/29/23 |
| GREEN ANDREW M | VP Regulatory VP Regulatory | Feb 23 | Sell | 12.94 | 1,747 | 22,606 | 24,102 | 03/01/23 |
| Mackin James P | President & CEO President & CEO | Feb 23 | Sell | 12.94 | 22,630 | 292,832 | 540,052 | 03/01/23 |
| Maier Dennis B | SVP, Operations SVP, Operations | Feb 23 | Sell | 12.94 | 2,330 | 30,150 | 48,436 | 03/01/23 |
| Stanton Marshall S. | SVP, Clinical & MD A.. SVP, Clinical & MD Affair | Feb 23 | Sell | 12.94 | 2,337 | 30,241 | 49,321 | 03/01/23 |
| Getz Matthew A | VP, Human Resources VP, Human Resources | Feb 23 | Sell | 12.94 | 1,600 | 20,704 | 35,128 | 03/01/23 |
| Horton Amy | VP, Chief Accounting.. VP, Chief Accounting Officer | Feb 17 | Sell | 14.1 | 18,000 | 253,800 | 102,663 | 02/21/23 |
| Horton Amy | VP, Chief Accounting.. VP, Chief Accounting Officer | Feb 17 | Option | 10.24 | 20,713 | 212,101 | 105,663 | 02/21/23 |
| Davis John E | Senior VP, Global Sa.. Senior VP, Global Sales | Feb 13 | Option | 10.24 | 8,745 | 89,549 | 120,017 | 02/15/23 |
| Horton Amy | VP, Chief Accounting.. VP, Chief Accounting Officer | Dec 14 | Sell | 13.57 | 3,226 | 43,777 | 101,950 | 12/16/22 |
| Maney Rochelle L. | VP, Quality VP, Quality | Aug 16 | Sell | 22.959 | 7,161 | 164,409 | 12,325 | 08/18/22 |
| Maier Dennis B | SVP, Operations SVP, Operations | Aug 09 | Sell | 21.62 | 5,762 | 124,574 | 22,807 | 08/10/22 |
| Mackin James P | President & CEO President & CEO | Feb 09 | Option | 11 | 21,277 | 234,047 | 314,817 | 02/11/22 |
| Mackin James P | President & CEO President & CEO | Feb 09 | Sell | 18 | 21,277 | 382,986 | 304,178 | 02/11/22 |
| Mackin James P | President & CEO President & CEO | Feb 08 | Option | 11 | 10,638 | 117,018 | 314,816 | 02/10/22 |
| Mackin James P | President & CEO President & CEO | Feb 08 | Sell | 17.75 | 10,638 | 188,824 | 304,178 | 02/10/22 |
| SEMEDO ANTHONY B. | Director Director | Nov 29 | Buy | 17.36 | 15,000 | 260,400 | 19,992 | 11/30/21 |
| Davis John E | Senior VP, Global Sa.. Senior VP, Global Sales | May 27 | Option | 26.24 | 5,402 | 141,748 | 84,638 | 05/27/21 |
| Davis John E | Senior VP, Global Sa.. Senior VP, Global Sales | May 27 | Sell | 29.67 | 12,739 | 377,966 | 71,899 | 05/27/21 |
| Maier Dennis B | Vice President, Oper.. Vice President, Operations | Feb 19 | Option | 21.55 | 6,630 | 142,876 | 23,211 | 02/19/21 |
| Maier Dennis B | Vice President, Oper.. Vice President, Operations | Feb 19 | Sell | 24.69 | 7,197 | 177,694 | 16,014 | 02/19/21 |
| Capps Scott B | VP, Clinical Researc.. VP, Clinical Research | Dec 16 | Option | 9.97 | 10,000 | 99,700 | 157,006 | 12/16/20 |
| Capps Scott B | VP, Clinical Researc.. VP, Clinical Research | Dec 16 | Sell | 21.34 | 8,366 | 178,530 | 148,640 | 12/16/20 |
| Horton Amy | VP, Chief Accounting.. VP, Chief Accounting Officer | Dec 16 | Option | 9.97 | 6,666 | 66,460 | 99,642 | 12/16/20 |
| Horton Amy | VP, Chief Accounting.. VP, Chief Accounting Officer | Dec 02 | Option | 9.97 | 6,666 | 66,460 | 99,642 | 12/02/20 |
| Horton Amy | VP, Chief Accounting.. VP, Chief Accounting Officer | Dec 02 | Sell | 20.78 | 6,666 | 138,519 | 92,976 | 12/02/20 |